Preferred Label : secukinumab;

Obsolete resource : false;

MeSH note : a fully human antibody to interleukin-17A for treatment of psoriasis, rheumatoid arthritis, and uveitis;

CISMeF synonym : AIN 457;

MeSH hyponym : AIN457; AIN-457;

Is substance : O;

UNII : DLG4EML025;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3501976/fr/cosentyx-secukinumab-rhumatisme-psoriasique
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
secukinumab
injections, subcutaneous
Interleukin Inhibitors
adult
Interleukin-17
evaluation of the transparency committee
arthritis, psoriatic
secukinumab

---
https://www.has-sante.fr/jcms/p_3539072/fr/cosentyx-secukinumab-biotherapies-par-voie-sous-cutanee-dans-les-maladies-inflammatoires-chroniques
2024
false
false
false
France
drug prescriptions
evaluation of the transparency committee
injections, subcutaneous
biological therapy
secukinumab
chronic disease

---
https://www.has-sante.fr/jcms/p_3470819/fr/cosentyx-secukinumab-hidradenite-suppuree-hs-maladie-de-verneuil
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
secukinumab
adult
injections, subcutaneous
evaluation of the transparency committee
hidradenitis suppurativa
secukinumab

---
https://www.has-sante.fr/jcms/p_3426148/fr/cosentyx-secukinumab-psoriasis-en-plaques-chez-l-enfant-et-l-adolescent
2023
false
false
false
France
secukinumab
evaluation of the transparency committee
psoriasis
secukinumab
child
adolescent

---
https://www.has-sante.fr/jcms/p_3367902/fr/cosentyx-secukinumab-psoriasis-en-plaques-de-l-adulte
2022
false
false
false
France
treatment outcome
psoriasis
adult
secukinumab
injections, subcutaneous
secukinumab
evaluation of the transparency committee

---
https://www.has-sante.fr/jcms/p_3305321/fr/cosentyx-150-mg-secukinumab-spondylarthrite-ankylosante
2022
false
false
false
France
injections, subcutaneous
evaluation of the transparency committee
secukinumab
spondylitis, ankylosing

---
https://www.has-sante.fr/jcms/p_3240424/fr/cosentyx
2021
false
false
false
France
French
secukinumab
secukinumab
evaluation of the transparency committee
antibodies, monoclonal

---
https://www.has-sante.fr/jcms/p_3302584/fr/cosentyx-75-mg-secukinumab
2021
false
false
false
France
insurance, health, reimbursement
secukinumab
Product containing only secukinumab in parenteral dose form (medicinal product form)
treatment outcome
evaluation of the transparency committee

---
https://www.has-sante.fr/jcms/p_3271033/fr/cosentyx-secukinumab-rhumatisme-psoriasique
2021
false
false
false
France
secukinumab
treatment outcome
insurance, health, reimbursement
adult
arthritis, psoriatic
drug therapy, combination
injections, subcutaneous
secukinumab
evaluation of the transparency committee
secukinumab
antibodies, monoclonal, humanized

---
https://www.has-sante.fr/jcms/p_3240240/fr/cosentyx
2021
false
false
false
France
French
treatment outcome
insurance, health, reimbursement
evaluation of the transparency committee
secukinumab
secukinumab
arthritis, psoriatic
Non-radiographic axial spondyloarthritis
spondylitis, ankylosing
psoriasis
adult
child
adolescent
injections, subcutaneous
antibodies, monoclonal

---
https://www.has-sante.fr/jcms/p_3233061/fr/cosentyx-enfant
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
secukinumab
secukinumab
psoriasis
child
adolescent
injections, subcutaneous
guidelines for drug use
Interleukin-17
evaluation of the transparency committee
antibodies, monoclonal

---
https://www.has-sante.fr/jcms/p_3211082/fr/cosentyx-spondyloarthrite-axiale-non-radiographique
2020
false
false
false
France
treatment outcome
insurance, health, reimbursement
secukinumab
injections, subcutaneous
Interleukin-17
secukinumab
adult
Non-radiographic axial spondyloarthritis
guidelines for drug use
evaluation of the transparency committee
antibodies, monoclonal

---
https://www.has-sante.fr/jcms/p_3097594/fr/cosentyx
2019
false
false
false
France
evaluation of the transparency committee
Cosentyx
secukinumab
antibodies, monoclonal

---
http://www.cri-net.com/fiches-pratiques-et-recommandations/dernieres-mises-a-jour/prise-encharge-secukinumab
2017
false
false
false
France
French
guidelines for drug use
injections, subcutaneous
continuity of patient care
secukinumab
secukinumab
adult
aged
Interleukin-17
arthritis, psoriatic
psoriasis
spondylitis, ankylosing
Evidence-Based medicine
secukinumab
antibodies, monoclonal
antibodies, monoclonal

---
http://www.has-sante.fr/portail/jcms/c_2631716/fr/cosentyx-spondylarthrite-ankylosante
2016
false
false
false
France
French
evaluation of the transparency committee
injections, subcutaneous
treatment outcome
secukinumab
secukinumab
adult
secukinumab
insurance, health, reimbursement
Interleukin-17
guidelines for drug use
spondylitis, ankylosing
antibodies, monoclonal
antibodies, monoclonal

---
http://www.has-sante.fr/portail/jcms/c_2633888/fr/cosentyx-rhumatisme-psoriasique
2016
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
secukinumab
secukinumab
injections, subcutaneous
secukinumab
insurance, health, reimbursement
adult
arthritis, psoriatic
drug therapy, combination
methotrexate
risk management
antibodies, monoclonal
antibodies, monoclonal

---
https://www.ema.europa.eu/medicines/human/EPAR/Cosentyx
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
secukinumab
secukinumab
secukinumab
drug approval
europe
psoriasis
adult
injections, subcutaneous
Interleukin-17
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
receptors, interleukin-17
drug evaluation, preclinical
antibodies, monoclonal
antibodies, monoclonal

---
http://www.has-sante.fr/portail/jcms/c_2561555/fr/cosentyx
http://www.has-sante.fr/portail/jcms/c_2561555/fr/cosentyx-secukinumab-immunosuppresseur-anti-interleukine
2015
false
false
false
false
France
French
evaluation of the transparency committee
secukinumab
secukinumab
secukinumab
Prefilled Syringe Dosage Form
Pre-filled Pen Syringe
insurance, health, reimbursement
treatment outcome
adult
psoriasis
Interleukin-17
injections, subcutaneous
Injectable Solution Dosage Form
guidelines for drug use
chronic disease
spondylitis, ankylosing
arthritis, psoriatic
antibodies, monoclonal
antibodies, monoclonal

---
Nous contacter.
04/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.